This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO 2020
ASCO 2020
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Press Releases
ASCO 2020 Prostate Cancer
Viewing 41-60 of 71 articles
ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
ASCO 2020: Efficacy of Enzalutamide + ADT in Metastatic Hormone-sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
ASCO 2020: Impact of Olaparib vs Physician’s Choice of New Hormonal Agent on Burden of Pain in mCRPC: PROfound
ASCO 2020: Phase III Study of Pembrolizumab plus Enzalutamide and ADT for Patients with Metastatic Hormone-Sensitive Prostate Cancer: KEYNOTE-991
ASCO 2020: A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Niraparib Plus Abiraterone Acetate and Prednisone versus Abiraterone Acetate and Prednisone in Patients with Metastatic Prostate Cancer (MAGNITUDE)
ASCO 2020: Therapeutic Approaches to Protein Degradation: PROTACs and E3 Ligase Modulation
ASCO 2020: Results of the Randomized Phase II Study of Sipuleucel-T +/- Radium-223 in Men with Bone-Metastatic Castration Resistant Prostate Cancer
ASCO 2020: A Randomized Controlled Trial of Video-Education or In-Person Genetic Counseling for Men with Prostate Cancer (ProGen)
ASCO 2020: Discussant: Novel Biomarkers in Prostate Cancer: Is the Tissue the Issue?
ASCO 2020: Baseline Circulating Tumor Cell Counts as a Prognostic Marker of PSA Response and Progression in mCSPC: Results from Phase III SWOG S1216
ASCO 2020: The Role of Neoadjuvant Therapy for Patients with Localized Prostate Cancer
ASCO 2020: Androgen Deprivation: Too Little, Too Much, or Just Right?
ASCO 2020: The Comprehensive Methylation Landscape of mCRPC Identifies New Phenotypic Subtypes: Results from the West Coast Prostate Cancer Dream Team
ASCO 2020: Is PSMA Right on Target?
ASCO 2020: First-in-Human Phase 1 Study of ARV-110, an Androgen Receptor PROTAC Degrader in Patients with Metastatic Castration-Resistant Prostate Cancer Following Enzalutamide and/or Abiraterone Acetate Treatment
ASCO 2020: Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: Results of Cohort 6 of the COSMIC-021 Study
ASCO 2020: Circulating Tumor DNA Dynamics Associate with Treatment Response and Radiological Progression-Free Survival: Analyses from a Randomized Phase II Trial in Metastatic Castration-Resistant Prostate Cancer
ASCO 2020: Radium-223 and Niraparib Treatment in Castrate-Resistant Prostate Cancer Patients with and without Prior Chemotherapy
ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone
ASCO 2020: Results from the HERO Phase III Trial Comparing Relugolix, an Oral GnRH Receptor Antagonist, versus Leuprolide Acetate for Advanced Prostate Cancer
1
2
3
4
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free